Search clinical trials for: GBS trivalent vaccine

Total 8178 results

GlaxoSmithKline
Novartis Vaccines

Completed

Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women

Streptococcus Agalactiae | GBS Disease

United States
GlaxoSmithKline

Completed

Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.

Streptococcus Agalactiae | Bacterial Infection Due to Streptococcus, Group B

Belgium
Guangxi Zhuang Autonomous Region Center for Disease...
Air Force Military Medical University, China; Beijing Tiantan Biological Products...

Completed

Randomized Controlled Trial for Immunogenicity and Safety Evaluation of Bivalent Types 1 and 3 Oral Poliovirus Vaccine (TTbOPV)

Poliomyelitis
Seqirus
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older

Influenza

Belgium
Shanghai Institute Of Biological Products

Completed

A Clinical Trial of A Quadrivalent Influenza Vaccine

Influenza

China
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old

Influenza

United States, Finland, Philippines, Thailand
Jiangsu Province Centers for Disease Control and...
Jiangsu Jindike Biotechnology Co., Ltd.

Completed

A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older

Influenza

China
University of Colorado, Denver
University of Alabama at Birmingham; All India Institute of Medical Sciences... and other collaborators

Completed

Influenza Immunization of Children in India

Influenza

India
National Institute of Allergy and Infectious Diseases...

Completed

Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma

Influenza

United States
Center for Disease Prevention and Control of Beijing...

Completed

Safety and Immunogenicity of Three Seasonal Trivalent Influenza Vaccines in China Military

Influenza

China
Seqirus

Completed

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

Influenza, Human

United States
Crucell Holland BV

Completed

Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults

Influenza

Belgium
National Institute of Allergy and Infectious Diseases...

Withdrawn

High Dose Influenza in Immunosuppressed Subjects

Influenza

United States
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above

Influenza

Germany
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age

Influenza Disease

Argentina, Australia, Chile, Philippines, South Africa
Butantan Institute

Completed

Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine

Influenza

Brazil
Insight Therapeutics, LLC
Brown University; Case Western Reserve University; Seqirus

Completed

Adjuvanted Influenza Vaccination in U.S. Nursing Homes

Influenza | Influenza-like Illness

United States
National Institute of Allergy and Infectious Diseases...
The Emmes Company, LLC

Completed

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone

Influenza

United States
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza (FluMist)

Influenza

South Africa
Sinovac Biotech Co., Ltd

Recruiting

A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months

Seasonal Influenza

China
Sinovac Biotech Co., Ltd

Completed

A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months

Seasonal Influenza

China
Vanderbilt University
University of Pittsburgh; MCM Vaccines B.V.

Completed

Standard Dose Versus High-Dose Inactivated Flu Vaccine in Pediatric Solid Organ Transplant Patients

Pediatric Solid Organ Transplant Patients

United States
The University of Hong Kong

Unknown

Safety and Efficacy of Intradermal Trivalent Influenza Vaccination in Institutionalized Older Adults

Influenza, Human

China
Wayne Sullender, M.D.
All India Institute of Medical Sciences, New Delhi; Centers for Disease Control...

Completed

Direct and Indirect Protection by Influenza Vaccine Given to Children in India

Influenza

India
UMC Utrecht
Netherlands Organisation for Scientific Research

Completed

Prevention of Respiratory Infections and MAnagement Among Children (PRIMAKid)

Recurrent Upper and Lower Respiratory Tract Infections (RTIs)

Netherlands
Vanderbilt University

Completed

Standard Versus High-Dose Trivalent Inactivated Flu Vaccine in Pediatric Acute Lymphoblastic Leukemia Patients

Pediatric Patients With Acute Lymphoblastic Leukemia

United States
Abbott Biologicals

Completed

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2012/2013 Season

Prophylaxis of Influenza

Germany
Sanofi Pasteur, a Sanofi Company

Completed

Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age

Influenza

China
University of Maryland, Baltimore

Completed

Salmonella Conjugates CVD 1000: Study of Responses to Vaccination With Trivalent Invasive Salmonella Disease Vaccine

Risk Reduction

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)

Influenza

Lithuania
Sinovac Biotech Co., Ltd

Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)

Seasonal Influenza

China
Sinovac Biotech Co., Ltd

Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)

Seasonal Influenza

China
Sanofi

Completed

Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects

Influenza | Myxovirus Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

FLU-VACS Comparative Study in Adults

Influenza

United States
Inova Health Care Services

Completed

Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.

Influenza, Human | Transplantation Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Influenza Virus Vaccines in Children and Adults

Influenza

United States
Ology Bioservices

Completed

Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older

Influenza

United States
Vanderbilt-Ingram Cancer Center

Completed

Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients

Adult Stem Cell Hematopoetic Transplant

United States
Shanghai Institute Of Biological Products

Completed

Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

Influenza

China
Novartis Vaccines

Completed

Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly

Influenza

Poland
University of Maryland, Baltimore

Completed

Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease

Risk Reduction

United States
Mount Sinai Hospital, Canada

Completed

Do Some Healthy Adults Consistently Have Systemic Reactions to Influenza Vaccines?

Influenza

Canada
Sanofi

Completed

Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years

Influenza | Flu

China
Fluart Innovative Vaccine Ltd, Hungary

Completed

Immunogenicity and Tolerability Study of FluvalAB FL-K-004 Trivalent Influenza Vaccine

Influenza

Hungary
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults

Influenza

United States, Puerto Rico, Canada
National Institute of Allergy and Infectious Diseases...
The Emmes Company, LLC

Completed

Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents

Influenza

United States
Novartis
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

Pandemic Influenza Disease

Finland, Germany
Roswell Park Cancer Institute

Completed

Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age

Influenza

United States

3

Subscribe